Finnish Institute of Health and Welfare, Helsinki, Finland.
ECDC Fellowship Programme, Public Health Microbiology path (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
Euro Surveill. 2023 Aug;28(31). doi: 10.2807/1560-7917.ES.2023.28.31.2200807.
BackgroundInvasive infections with beta-haemolytic streptococci of Lancefield groups A (iGAS), B (iGBS) and C/G (iGCGS) are a major cause of morbidity and mortality worldwide.AimWe studied incidence trends of invasive beta-haemolytic streptococcal infections in Finland, focusing on iGCGS.MethodsWe conducted a retrospective register-based study. Cases were defined as isolations from blood and/or cerebrospinal fluid and retrieved from the National Infectious Disease Register where all invasive cases are mandatorily notified.ResultsBetween 2006 and 2020, the mean annual incidence was 4.1 per 100,000 for iGAS (range: 2.1-6.7), 5.2 for iGBS (4.0-6.3) and 10.1 for iGCGS (5.4-17.6). The incidence displayed an increasing trend for all groups, albeit for iGBS only for individuals 45 years and older. The increase was particularly sharp for iGCGS (8% annual relative increase). The incidence rate was higher in males for iGCGS (adjusted incidence rate ratio (IRR) = 1.6; 95% confidence interval (CI): 1.5-1.8) and iGAS (adjusted IRR = 1.3; 95% CI: 1.1-1.4); for iGBS, the association with sex was age-dependent. In adults, iGCGS incidence increased significantly with age. Recurrency was seen for iGCGS and secondarily iGBS, but not for iGAS. Infections with iGCGS and iGBS peaked in July and August.ConclusionsThe incidence of invasive beta-haemolytic streptococcal infections in Finland has been rising since 2006, especially for iGCGS and among the elderly population. However, national surveillance still focuses on iGAS and iGBS, and European Union-wide surveillance is lacking. We recommend that surveillance of iGCGS be enhanced, including systematic collection and typing of isolates, to guide infection prevention strategies.
A、B 和 C/G 组β-溶血性链球菌(iGAS、iGBS 和 iGCGS)的侵袭性感染是全世界发病率和死亡率的主要原因。
我们研究了芬兰侵袭性β-溶血性链球菌感染的发病率趋势,重点关注 iGCGS。
我们进行了一项回顾性基于登记的研究。病例定义为从血液和/或脑脊液中分离出来的,并从国家传染病登记处检索到,所有侵袭性病例都必须报告。
2006 年至 2020 年,iGAS 的年平均发病率为每 10 万人 4.1 例(范围:2.1-6.7),iGBS 为每 10 万人 5.2 例(4.0-6.3),iGCGS 为每 10 万人 10.1 例(5.4-17.6)。所有组的发病率均呈上升趋势,尽管 iGBS 仅在 45 岁及以上人群中如此。iGCGS 的增幅尤其明显(年相对增长率为 8%)。iGCGS 的发病率在男性中更高(调整发病率比 (IRR) = 1.6;95%置信区间 (CI):1.5-1.8)和 iGAS(调整 IRR = 1.3;95%CI:1.1-1.4);对于 iGBS,与性别相关的是年龄。在成年人中,iGCGS 的发病率随年龄增长而显著增加。iGCGS 和继发性 iGBS 可见复发,但 iGAS 则没有。iGCGS 和 iGBS 的感染在 7 月和 8 月达到高峰。
自 2006 年以来,芬兰侵袭性β-溶血性链球菌感染的发病率一直在上升,尤其是 iGCGS 和老年人群。然而,国家监测仍侧重于 iGAS 和 iGBS,欧盟范围内的监测则缺乏。我们建议加强对 iGCGS 的监测,包括系统收集和分型分离株,以指导感染预防策略。